Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.59 |
| ▸ | NQO2 | P16083 | 4/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088345 | 1.00 | CYP1A1 (0.59) | CYP1A1CYP1B1CYP1A2TUBB4ATUBB | |
| SCHEMBL25990002 | 0.85 | TUBB1 (0.51) | CYP1A1CYP1B1CYP1A2TUBB4ATUBB | |
| SCHEMBL13349799 | 0.84 | JUN (0.69) | NFE2L2PTGS1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25990220 | 0.84 | APP (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30293787 | 0.84 | TYR (0.67) | CYP1A2NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL11910660 | 0.84 | TYR (0.67) | CYP1A2NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL4257522 | 0.84 | TYR (0.67) | CYP1A2NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL20087219 | 0.84 | TYR (0.67) | CYP1A2NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL9431599 | 0.83 | CYP1A1 (0.80) | CYP1A1CYP1B1CYP1A2TUBB4ATUBB | |
| SCHEMBL9586847 | 0.83 | CYP1A1 (0.80) | CYP1A1CYP1B1CYP1A2TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090202666-A1 | COSMETIC USE OF A CASSUMUNARIN, AN ARYLBUTENOID, AND/OR A BOTANICAL EXTRACT CONTAINING THEM | CHANEL PARFUMS BEAUTE (FR) | 2009-08-13 | — | — | US | claimed |
| EP-1870136-A1 | Cosmetic use of a cussumunarine, an arylbutenoid and/or a plant extract containing the same | Chanel Parfums Beauté (FR) | 2007-12-26 | — | — | EP | claimed |
| WO-2007144270-A1 | COSMETIC USE OF A CASSUMUNARIN, AN ARYLBUTENOID, AND/OR A BOTANICAL EXTRACT CONTAINING THEM | CHANEL PARFUMS BEAUTE (FR) | 2007-12-21 | — | — | WO | claimed |
| US-20230130823-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) | 2023-04-27 | — | — | US | disclosed |
| US-20220409638-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | MEDICON PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20190307780-A1 | Anti-Inflammatory Compounds and Uses Thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20090202666-A1 | COSMETIC USE OF A CASSUMUNARIN, AN ARYLBUTENOID, AND/OR A BOTANICAL EXTRACT CONTAINING THEM | CHANEL PARFUMS BEAUTE (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1870136-A1 | Cosmetic use of a cussumunarine, an arylbutenoid and/or a plant extract containing the same | Chanel Parfums Beauté (FR) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307780-A1 | Anti-Inflammatory Compounds and Uses Thereof | TNF, NFKBIA, IL6 | CYP1A1 1048/4885CYP1B1 1151/4885CYP1A2 647/4885 |
| US-20230130823-A1 | PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF | BAD, BAX, PDCD4 | CYP1A1 3806/4885CYP1B1 2250/4885CYP1A2 3500/4885 |
| US-20090202666-A1 | COSMETIC USE OF A CASSUMUNARIN, AN ARYLBUTENOID, AND/OR A BOTANICAL EXTRACT CONTAINING THEM | ARNT, AHR, CUTA | CYP1A1 109/4885CYP1B1 66/4885CYP1A2 204/4885 |
| US-20220409638-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | TNF, NFKBIA, IL6 | CYP1A1 1048/4885CYP1B1 1151/4885CYP1A2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.